48 results on '"Coelho dos Reis, Jordana Grazziela Alves"'
Search Results
2. Rhythmic profile of memory T and B-cells along childhood and adolescence
3. New anti-SARS-CoV-2 aminoadamantane compounds as antiviral candidates for the treatment of COVID-19
4. Serum soluble mediators as prognostic biomarkers for morbidity, disease outcome, and late-relapsing hepatitis in yellow fever patients
5. Plasma immune mediators as laboratorial biomarkers for Sickle Cell Disease patients according to the hydroxyurea therapy and disease severity
6. Algorithms for predicting COVID outcome using ready-to-use laboratorial and clinical data.
7. Association between inflammatory molecules, nitric oxide metabolites and leg ulcers in individuals with sickle cell anemia
8. Impact of HIV co-infection on immunological biomarker profile of HTLV-1 infected patients
9. Remodeling of immunological biomarkers in patients with chronic hepatitis C treated with direct-acting antiviral therapy
10. Performance of Immunological Assays for Universal and Differential Diagnosis of HTLV-1/2 Infection in Candidates for Blood Donations from the Brazilian Amazon
11. Different profiles of chemokines, cytokines and cell growth factors in plasma samples from patients with leprosy, leprosy reactions and households contacts
12. Performance of immunological assays for universal and differential diagnosis of HTLV-1/2 infection in candidates for blood donations from the Brazilian Amazon.
13. Taming the SARS-CoV-2-mediated proinflammatory response with BromAc®
14. Phenotypic and functional features of innate and adaptive immunity as putative biomarkers for clinical status and leprosy reactions
15. Surveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8+ T cells
16. Systemic Immunological changes in patients with distinct clinical outcomes during Mycobacterium tuberculosis infection
17. Strategies for serum chemokine/cytokine assessment as biomarkers of therapeutic response in HCV patients as a prototype to monitor immunotherapy of infectious diseases
18. Design, development, and validation of multi-epitope proteins for serological diagnosis of Zika virus infections and discrimination from dengue virus seropositivity.
19. An immunostimulatory glycolipid that blocks SARS-CoV-2, RSV, and influenza infections in vivo
20. Panoramic snapshot of serum soluble mediator interplay in pregnant women with convalescent COVID-19: an exploratory study
21. Diversity of HLA-A2-Restricted and Immunodominant Epitope Repertoire of Human T-Lymphotropic Virus Type 1 (HTLV-1) Tax Protein: Novel Insights among N-Terminal, Central and C-Terminal Regions
22. Physiology and Pathology of Infectious Diseases: The Autoimmune Hypothesis of Chagas Disease
23. In silico and in vitro arboviral MHC class I-restricted-epitope signatures reveal immunodominance and poor overlapping patterns
24. The role of mucosal-associated invariant T cells in visceral leishmaniasis
25. Dual role of IL-12 in the therapeutic efficacy or failure during combined PEG-Interferon-α2A and ribavirin therapy in patients with chronic hepatitis C
26. Anti-Tax antibody levels in asymptomatic carriers, oligosymptomatic carriers, patients with rheumatologic disease or with HAM/TSP do not correlate with HTLV-1 proviral load
27. Applicability of an optimized non-conventional flow cytometry method to detect anti- Trypanosoma cruzi immunoglobulin G for the serological diagnosis and cure assessment following chemotherapeutic treatment of Chagas disease
28. Serum Soluble Mediator Profiles and Networks During Acute Infection With Distinct DENV Serotypes
29. A New Flow Cytometry-Based Single Platform for Universal and Differential Serodiagnosis of HTLV-1/2 Infection
30. Serum soluble mediator waves and networks along healthy ageing
31. Corrigendum: Algorithms for predicting COVID outcome using ready-to-use laboratorial and clinical data.
32. Diagnostic tool based on an HTLV-1-Tax expression system in eukaryotic cells using a poxvirus vector
33. O-11 REMODELING OF IMMUNOLOGICAL BIOMARKERS IN PATIENTS WITH CHRONIC HEPATITIS C TREATED WITH DIRECTACTING ANTIVIRAL THERAPY
34. Performance of IgG and IgG1 anti-HTLV-1 reactivity by an indirect immunofluorescence flow cytometric assay for the identification of persons infected with HTLV-1, asymptomatic carriers and patients with myelopathy
35. Anti-fixed Leishmania chagasi promastigotes IgG antibodies detected by flow cytometry (FC-AFPA-IgG) as a tool for serodiagnosis and for post-therapeutic cure assessment in American visceral leishmaniasis
36. IL-17 as a putative hallmark of intense arthralgia and age-related serum immune mediator networks during acute chikungunya fever
37. CCL3, CCL5, IL-15, IL-1Ra and VEGF compose a reliable algorithm to discriminate classes of adverse events following 17DD-YF primary vaccination according to cause-specific definitions
38. Association between inflammatory molecules, nitric oxide metabolites and leg ulcers in individuals with sickle cell anemia
39. Establishing tools for early diagnosis of congenital toxoplasmosis: Flow cytometric IgG avidity assay as a confirmatory test for neonatal screening
40. Immunological signature of the different clinical stages of the HTLV-1 infection: establishing serum biomarkers for HTLV-1-associated disease morbidity
41. Avaliação do desempenho de parâmetros imunológicos como indicadores de progressão clínica da infecção crônica pelo HTLV-1
42. Immunological Profile of HTLV-1-Infected Patients Associated with Infectious or Autoimmune Dermatological Disorders
43. In-house ELISA method to analyze anti-Trypanosoma cruzi IgG reactivity for differential diagnosis and evaluation of Chagas disease morbidity
44. Avaliação do desempenho de parâmetros imunológicos como indicadores de progressão clínica da infecção crônica pelo HTLV-1
45. Distinct CD8 + T-cell types Associated with COVID-19 Severity in Unvaccinated HLA-A2 + Patients.
46. MR1 blockade drives differential impact on integrative signatures based on circuits of circulating immune cells and soluble mediators in visceral leishmaniasis.
47. Surveillance of SARS-CoV-2 immunogenicity: loss of immunodominant HLA-A*02-restricted epitopes that activate CD8 + T cells.
48. [Evaluation of the performance of immunological parameters as indicators for clinical progression of chronic HTLV-1 infection].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.